Omeros Announces Publication Of Phase 2 Clinical Results For OMS103HP In Arthroscopy
Thursday, June 30th, 2011Latest news:
Likewise Included In: Cardiovascular / Cardiology ; Clinical Trials / Dose Trials
Omeros Pot (NASDAQ: OMER) reported the issue of results from a Form 2 visitation investigation OMS103HP in patients undergoing arthroscopic overtone meniscectomy operation. OMS103HP is Omeros’ intersection prospect organism highly-developed for use during arthroscopic procedures and is intentional to offer a multimodal access to preemptively closure the incendiary shower induced by arthroscopy.
